| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$49,290,024 |
|
|
|
Indirect Value
|
$10,089,189 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$59,379,213 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 57.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-12-18 |
4 |
OE |
$21.25 |
$99,981 |
D/D |
4,705 |
24,391 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-02-13 |
4 |
S |
$316.55 |
$7,209,136 |
D/D |
(22,612) |
24,391 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-04-13 |
4 |
OE |
$52.03 |
$680,500 |
D/D |
13,079 |
24,459 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,688 |
24,715 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-08 |
4 |
S |
$340.60 |
$715,340 |
D/D |
(2,100) |
25,173 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-29 |
4 |
OE |
$8.77 |
$219,250 |
D/D |
25,000 |
25,350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-11-25 |
4 |
D |
$362.75 |
$2,174,324 |
D/D |
(5,994) |
26,461 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-01 |
4 |
D |
$464.98 |
$3,595,225 |
D/D |
(7,732) |
26,762 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
OE |
$7.41 |
$296,400 |
D/D |
40,000 |
27,127 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2009-07-24 |
4 |
D |
$20.14 |
$1,260,301 |
D/D |
(62,577) |
27,236 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-07 |
4 |
S |
$340.39 |
$252,304 |
D/D |
(741) |
27,273 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-12-16 |
4 |
OE |
$52.03 |
$99,950 |
D/D |
1,921 |
27,594 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-06 |
4 |
D |
$336.11 |
$6,894,624 |
D/D |
(20,513) |
28,014 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-11-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,605 |
28,809 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2007-04-20 |
4 |
OE |
$8.77 |
$219,250 |
D/D |
25,000 |
29,297 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-18 |
4 |
OE |
$115.29 |
$1,931,915 |
D/D |
16,757 |
30,284 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-01 |
4 |
OE |
$145.70 |
$2,091,724 |
D/D |
10,544 |
30,814 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-24 |
4 |
S |
$295.09 |
$3,366,092 |
D/D |
(11,407) |
31,973 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-21 |
4 |
D |
$510.02 |
$5,964,174 |
D/D |
(11,694) |
32,256 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-11-25 |
4 |
OE |
$52.03 |
$520,300 |
D/D |
10,000 |
32,455 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-14 |
4 |
D |
$475.56 |
$5,577,368 |
D/D |
(11,728) |
32,517 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-12 |
4 |
OE |
$52.03 |
$1,300,750 |
D/D |
25,000 |
36,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
OE |
$52.03 |
$1,300,750 |
D/D |
25,000 |
36,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2016-02-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,500 |
40,470 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-05-14 |
4 |
D |
$516.69 |
$18,073,300 |
D/D |
(34,979) |
41,801 |
0 |
- |
|
140 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
